Blosozumab
SOST | |
|---|---|
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6462H9852N1684O2030S46 |
| Molar mass | 145086.42 g·mol−1 |
  (what is this?) (verify) | |
Blosozumab binds
SOST, a negative regulator of osteoblast activity. Blocking SOST activity can lead to increased bone density.[1] Blosozaumab has been studied with regards to the treatment of osteoporosis in both men and postmenopausal women. Clinical trials with Blosozumab have shown the antibody to be well tolerated and effective in producing a bone anabolic effect.[2]
Blosozumab was developed by Eli Lilly and Company.
References
- ^ World Health Organization (2011). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 105" (PDF). WHO Drug Information. 25 (2).[dead link]
- PMID 23996473.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |